Module 4.2.1 — Pharmacology Study Reports (TILA-278)
📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Nonclinical study documentation for TILA-278.
Why it exists. Animal pharmacology, PK, and toxicology supporting the safety of clinical dosing.
How it is produced here. No real animal studies were run for this portfolio, so this is deep-knowledge mock: the study designs, endpoints, and conclusions are realistic domain content standing in for real laboratory data.
Format & governing standard. ICH M4S / S6(R1)
Module 4.2.1 — Pharmacology Study Reports (TILA-278)
| Field | Value |
|---|---|
| Document ID | M4-2.1 |
| Version | 1.0 |
| Compound | TILA-278 (anti-TL1A antagonist / IL-22R agonist bispecific) |
| Standard | ICH M4S / S6(R1) |
| Confidentiality | Confidential |
Nonclinical study documentation for TILA-278.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-07-08 | Nonclinical | Initial issue |
4.2.1 Pharmacology
TILA-278 is a humanized bispecific immunoglobulin G1 (IgG1) monoclonal antibody comprising two independent antigen-binding arms on a single molecule: an anti-TL1A (TNFSF15) antagonist arm that neutralises the pro-inflammatory cytokine TL1A, and an interleukin-22 receptor alpha-1 (IL-22RA1) agonist arm that reproduces IL-22–like epithelial signalling. The two activities are mechanistically complementary in ulcerative colitis (UC): TL1A neutralisation attenuates TH1/TH17-driven mucosal inflammation and pro-fibrotic signalling, while IL-22R agonism drives intestinal epithelial regeneration, antimicrobial-peptide production and mucosal-barrier repair. TILA-278 is administered subcutaneously (SC).
This module presents the primary pharmacodynamic (PD), secondary PD and safety pharmacology study reports supporting the mechanism of action and the first-in-human (FIH) safety assessment of TILA-278 (Sponsor: Virtual Biopharma Inc.). Because both human targets are engaged with strict species specificity and are not adequately bound in conventional rodents, in vivo primary pharmacology was characterised using a species-matched murine surrogate bispecific antibody (designated mVB-278) in established models of experimental colitis, consistent with the surrogate-molecule approach endorsed by ICH S6(R1). Safety pharmacology endpoints (cardiovascular, respiratory, central nervous system [CNS]) were evaluated under Good Laboratory Practice (GLP) as functional measures integrated within the pivotal cynomolgus monkey repeat-dose toxicity study, consistent with ICH S6(R1), S7A and S7B/E14. A dedicated thorough QT study was not conducted; the waiver rationale for this large-molecule therapeutic is provided in Section 4.2.1.3.4.
Data summarised here are cross-referenced to the Pharmacology Written and Tabulated Summaries (Sections 2.6.2 and 2.6.3) and integrated in the Nonclinical Overview (Section 2.4).
Study report inventory
| CTD sub-section | Study No. | Study title (abbreviated) | Test system | GLP | Report No. |
|---|---|---|---|---|---|
| 4.2.1.1 | TILA278-NC-PD-001 | Binding affinity and kinetics to TL1A and IL-22RA1 across species (SPR) | Cell-free (SPR) | No | R-PD-001 |
| 4.2.1.1 | TILA278-NC-PD-002 | In vitro TL1A/DR3 neutralisation potency | Reporter + primary human T cells | No | R-PD-002 |
| 4.2.1.1 | TILA278-NC-PD-003 | In vitro IL-22RA1 agonism potency (pSTAT3, target-gene induction) | Colonic epithelial lines / organoids | No | R-PD-003 |
| 4.2.1.1 | TILA278-NC-PD-004 | Simultaneous dual target engagement and ex vivo human colonic mucosa activity | Dual-binding / ex vivo mucosa | No | R-PD-004 |
| 4.2.1.1 | TILA278-NC-PD-010 | Efficacy of mVB-278 in acute DSS-induced colitis | Mouse (C57BL/6) | No | R-PD-010 |
| 4.2.1.1 | TILA278-NC-PD-011 | Efficacy of mVB-278 in CD45RB^high T-cell transfer chronic colitis | Mouse (Rag2^-/-) | No | R-PD-011 |
| 4.2.1.1 | TILA278-NC-PD-012 | Efficacy of mVB-278 in chronic DSS colitis with intestinal fibrosis | Mouse (C57BL/6) | No | R-PD-012 |
| 4.2.1.2 | TILA278-NC-PD-020 | Target selectivity across TNF and IL-10 cytokine superfamilies | Cell-free / cell-based panel | No | R-PD-020 |
| 4.2.1.2 | TILA278-NC-PD-021 | In vitro cytokine-release and effector-function assessment | Human whole blood / PBMC | No | R-PD-021 |
| 4.2.1.3 | TILA278-NC-SP-001 | Safety pharmacology (CV/respiratory/CNS), integrated | Cynomolgus monkey | Yes | R-SP-001 |
Tissue cross-reactivity (GLP; human and cynomolgus tissue panels, Study TILA278-NC-TX-002) is reported under Toxicology (Section 4.2.3.7) and summarised in Section 4.2.1.2.4.
Test articles
TILA-278 (clinical molecule). Recombinant humanised IgG1 bispecific antibody expressed in a Chinese hamster ovary (CHO) cell line and purified by protein-A capture, polishing chromatography and dedicated viral-clearance steps. The lots used in pharmacology studies were representative of the intended clinical process and released against binding potency for both arms (anti-TL1A neutralisation and IL-22R agonism) as well as identity, purity/impurity (aggregate, charge-variant and glycosylation) attributes. The IgG1 Fc region was retained; effector-function characterisation is summarised in Section 4.2.1.2.3.
mVB-278 (murine surrogate). A bispecific antibody on a mouse IgG1 backbone bearing an anti-mouse Tl1a antagonist arm and a mouse IL-22RA1 agonist arm, engineered to reproduce the geometry, valency (one binding site per target) and complementary dual mechanism of TILA-278 in a mouse-reactive format. The relative in vitro potency of mVB-278 against its murine targets was benchmarked against TILA-278 against its human targets (Section 4.2.1.1.2, Table 4.2.1-3) to justify its use as a pharmacologically analogous tool for in vivo proof of mechanism.
4.2.1.1 Primary Pharmacodynamics
4.2.1.1.1 Mechanistic rationale
TL1A signals through its receptor DR3 (TNFRSF25) on activated T cells and innate lymphoid cells, amplifying TH1/TH17 effector responses and promoting mucosal fibroblast activation; elevated TL1A/DR3 signalling is implicated in the inflammatory and fibrostenotic components of inflammatory bowel disease. The anti-TL1A arm of TILA-278 binds soluble and membrane TL1A and blocks the TL1A–DR3 interaction, thereby dampening downstream NF-κB activation and effector cytokine production. IL-22 signals through a heterodimeric receptor (IL-22RA1/IL-10RB) that is expressed predominantly on epithelial cells and, upon activation, drives STAT3 phosphorylation, expression of regenerating islet-derived (REG3) proteins and other antimicrobial peptides, mucin production and epithelial proliferation. The IL-22R agonist arm of TILA-278 engages IL-22RA1 and promotes IL-22RA1/IL-10RB assembly to reproduce this regenerative, barrier-restorative signalling. Delivering both activities from a single molecule is intended to couple resolution of inflammation with active mucosal healing.
4.2.1.1.2 In vitro primary pharmacology
Binding affinity and kinetics (Study TILA278-NC-PD-001). Equilibrium dissociation constants (K_D) and binding kinetics of each arm were determined by surface plasmon resonance (SPR) at 37 °C against recombinant TL1A and IL-22RA1 from human, cynomolgus monkey, mouse and rat. TILA-278 bound human and cynomolgus targets with high, comparable affinity and showed no measurable binding to rodent targets, establishing the pharmacological basis for species selection in toxicology (cynomolgus) and for the surrogate approach in efficacy models (mouse).
Table 4.2.1-1. Binding affinity of TILA-278 arms across species (SPR, 37 °C). ^a
| Arm / target | Species | k_a (M⁻¹s⁻¹) | k_d (s⁻¹) | K_D |
|---|---|---|---|---|
| Anti-TL1A / TL1A | Human | 3.5 × 10⁵ | 5.2 × 10⁻⁵ | 0.15 nM |
| Anti-TL1A / TL1A | Cynomolgus | 3.1 × 10⁵ | 6.8 × 10⁻⁵ | 0.22 nM |
| Anti-TL1A / TL1A | Mouse / Rat | — | — | No binding (>1 µM) |
| IL-22R agonist / IL-22RA1 | Human | 2.0 × 10⁵ | 3.6 × 10⁻⁴ | 1.8 nM |
| IL-22R agonist / IL-22RA1 | Cynomolgus | 1.9 × 10⁵ | 4.6 × 10⁻⁴ | 2.4 nM |
| IL-22R agonist / IL-22RA1 | Mouse / Rat | — | — | No binding (>1 µM) |
^a Representative values from a qualified assay; numerical values are.
TL1A neutralisation potency (Study TILA278-NC-PD-002). Antagonism was quantified in (i) a DR3-expressing NF-κB reporter cell line stimulated with recombinant human TL1A and (ii) an inhibition-of-function assay measuring TL1A/IL-12/IL-18-driven interferon-gamma (IFN-γ) release from primary human T cells. TILA-278 produced concentration-dependent, complete inhibition in both formats.
IL-22R agonism potency (Study TILA278-NC-PD-003). Agonism was quantified by STAT3 phosphorylation (pSTAT3) in Colo205 colonic epithelial cells and by induction of REG3A and other IL-22 target genes / antimicrobial peptides in HT-29 cells, with recombinant human IL-22 (rhIL-22) as the reference agonist. TILA-278 was a full agonist relative to rhIL-22, and its activity was confirmed in primary human colonic epithelial organoids (increased proliferation and MUC2 expression).
Table 4.2.1-2. In vitro functional potency of TILA-278. ^a
| Activity | Assay / readout | Test system | Potency | Maximal effect |
|---|---|---|---|---|
| TL1A neutralisation | DR3/NF-κB reporter inhibition | HEK reporter | IC₅₀ 0.35 nM | ~100% inhibition |
| TL1A neutralisation | IFN-γ release inhibition | Primary human T cells | IC₅₀ 0.80 nM | ~95% inhibition |
| IL-22R agonism | pSTAT3 induction | Colo205 | EC₅₀ 2.5 nM | 90% of rhIL-22 E_max |
| IL-22R agonism | REG3A / antimicrobial-peptide induction | HT-29 | EC₅₀ 3.0 nM | 88% of rhIL-22 E_max |
| IL-22R agonism | Proliferation / MUC2 | Human colonic organoids | EC₅₀ 4.1 nM | Comparable to rhIL-22 |
^a Representative values from qualified/validated assays; numerical values are.
Simultaneous dual engagement and ex vivo activity (Study TILA278-NC-PD-004). A dual-binding bridging assay confirmed that a single TILA-278 molecule can engage TL1A and IL-22RA1 concurrently without steric interference, and a cell-based co-culture demonstrated that both activities are retained when both targets are present. In ex vivo cultured human inflamed colonic mucosa, TILA-278 reduced secretion of TL1A-dependent effector cytokines while increasing epithelial IL-22 target-gene expression, reproducing the intended dual pharmacology in human tissue.
Surrogate benchmarking. To justify in vivo use of mVB-278, its potency against murine targets was compared with that of TILA-278 against human targets in matched assay formats (Table 4.2.1-3), confirming that the surrogate reproduces both arms with a comparable potency profile.
Table 4.2.1-3. Potency comparison — TILA-278 (human targets) vs mVB-278 (mouse targets). ^a
| Activity | Readout | TILA-278 (human) | mVB-278 (mouse) |
|---|---|---|---|
| TL1A neutralisation | Reporter IC₅₀ | 0.35 nM | 0.48 nM |
| IL-22R agonism | pSTAT3 EC₅₀ | 2.5 nM | 3.3 nM |
^a Representative values; numerical values are.
4.2.1.1.3 In vivo primary pharmacology (surrogate, murine colitis models)
The in vivo pharmacology of the dual mechanism was demonstrated with mVB-278 across three complementary models addressing acute injury, chronic T-cell-driven inflammation, and the fibrotic component of disease. mVB-278 was administered SC; a matched isotype control (mouse IgG1) and, where informative, monospecific parental arms (anti-Tl1a alone, IL-22R agonist alone) were included to attribute effects to each mechanism and to the bispecific combination.
Acute dextran sulfate sodium (DSS) colitis (Study TILA278-NC-PD-010; C57BL/6). In DSS-induced colitis, mVB-278 produced dose-dependent reductions in disease activity index (weight loss, stool consistency, occult blood), preservation of colon length, and lower histopathology scores versus isotype control. The bispecific was superior to either monospecific parental arm alone, consistent with combined suppression of inflammation and acceleration of epithelial repair.
CD45RB^high T-cell transfer chronic colitis (Study TILA278-NC-PD-011; Rag2^-/- recipients). In this chronic, TH1/TH17-driven model, mVB-278 reduced clinical and histological colitis and lowered mucosal effector cytokines (IFN-γ, IL-17A, TNF), reflecting the anti-TL1A mechanism, while increasing epithelial IL-22 target genes (Reg3γ) and improving barrier integrity, reflecting the IL-22R-agonist mechanism.
Chronic DSS colitis with fibrosis (Study TILA278-NC-PD-012; C57BL/6). In a repeated-cycle DSS model incorporating a fibrotic endpoint, mVB-278 reduced colonic collagen deposition and α-smooth-muscle-actin (α-SMA) expression alongside inflammatory improvement, supporting an anti-fibrotic contribution of TL1A neutralisation.
Table 4.2.1-4. Summary of in vivo surrogate efficacy studies (mVB-278, SC). ^a
| Study | Model / species | Design | Key PD outcomes vs control |
|---|---|---|---|
| PD-010 | Acute DSS / C57BL/6 | Dose-ranging; isotype + parental arms | ↓ disease activity index, ↑ colon length, ↓ histology score; bispecific > either arm alone |
| PD-011 | CD45RB^high transfer / Rag2^-/- | Therapeutic dosing; isotype control | ↓ histological colitis; ↓ IFN-γ/IL-17A/TNF; ↑ Reg3γ; restored barrier (↓ FITC-dextran permeability) |
| PD-012 | Chronic DSS + fibrosis / C57BL/6 | Repeated cycles; isotype control | ↓ collagen and α-SMA; ↓ inflammation; anti-fibrotic effect |
^a Directional outcomes reflect the intended pharmacology; effect magnitudes and dose levels are.
Exposure–response. Across models, efficacy was dose- and exposure-ordered, and mucosal-healing biomarkers (epithelial proliferation, Reg3γ, MUC2) tracked with target engagement of the IL-22R arm while effector-cytokine suppression tracked with the anti-Tl1a arm, supporting a mechanism-based, exposure-driven pharmacological effect. These relationships informed PK/PD-based projection of the clinically active exposure range (Sections 2.6.4 and 2.7.2).
Translational relevance (cross-reference to Module 5). The dual, dose-ordered nonclinical pharmacology is consistent with the clinical proof-of-concept subsequently observed in the Phase 2b induction study (Study TILA278-201), in which Week-12 clinical remission was dose-ordered — TILA-278 High 37.3% (106/284), Low 16.2% (46/283) and Placebo 0.7% (2/273) — corroborating the mechanistic hypothesis established in this pharmacology package.
4.2.1.2 Secondary Pharmacodynamics
4.2.1.2.1 Target selectivity (Study TILA278-NC-PD-020)
The selectivity of each arm was assessed against structurally related members of the relevant cytokine/receptor families. The anti-TL1A arm was tested against a panel of TNF-superfamily ligands (including TNF-α, LTα, FasL/CD95L, TRAIL, LIGHT, RANKL), and the IL-22R agonist arm against IL-10-family members and their receptors (including IL-10, IL-19, IL-20, IL-24, IL-26 and IL-20RA/IL-20RB/IL-22RA2). No specific binding or functional activity was detected against off-target family members, confirming that both activities are highly selective for their intended targets. A broad in vitro membrane-proteome (cell-microarray) screen against the human surfaceome identified no unexpected off-target binding.
4.2.1.2.2 Cytokine release and immune-activation potential (Study TILA278-NC-PD-021)
In vitro cytokine-release assessment in human whole blood and peripheral blood mononuclear cells (soluble-phase and immobilised formats, with appropriate positive controls) showed no meaningful pro-inflammatory cytokine release attributable to TILA-278. This is mechanistically consistent with an antibody whose activities are ligand neutralisation and defined epithelial-receptor agonism rather than T-cell activation.
4.2.1.2.3 Effector function
Fc-mediated effector-function assays (FcγR and C1q binding; antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against relevant target-expressing cells) indicated low effector engagement under the conditions tested. As the anti-TL1A arm neutralises a soluble/shed ligand and the IL-22R arm acts as an epithelial agonist, effector function is not required for the intended pharmacology and no effector-driven safety liability was identified.
4.2.1.2.4 Tissue cross-reactivity (cross-reference)
GLP tissue cross-reactivity of TILA-278 on full panels of human and cynomolgus tissues (Study TILA278-NC-TX-002) is reported in Section 4.2.3.7. Staining was consistent with the known distribution of the intended targets (e.g., gastrointestinal epithelium and lymphoid/immune cell populations), with no unexpected reactivity that would indicate an off-target safety concern; the cynomolgus tissue-binding profile supported its selection as the pharmacologically relevant toxicology species.
4.2.1.3 Safety Pharmacology
4.2.1.3.1 Strategy
Consistent with ICH S6(R1) and S7A, and given that the pharmacologically relevant species is the cynomolgus monkey, safety pharmacology endpoints for the cardiovascular, respiratory and central nervous systems were evaluated as functional measures integrated into the pivotal GLP repeat-dose SC toxicity study in cynomolgus monkeys (Study TILA278-NC-SP-001, conducted within toxicology study TILA278-NC-TX-004). This integrated design provides functional assessment at pharmacologically and toxicologically relevant exposures while reducing animal use. The general study design comprised once-weekly SC administration of vehicle, 10, 30 and 100 mg/kg over the dosing phase, with a recovery cohort.
4.2.1.3.2 Cardiovascular system
Cardiovascular function was assessed by jacketed external telemetry, with recordings before dosing and after the first and last doses. Heart rate, systolic/diastolic/mean arterial blood pressure, and quantitative electrocardiogram intervals (RR, PR, QRS, QT and heart-rate-corrected QTcF), together with qualitative waveform morphology, were evaluated. There were no TILA-278-related effects on any cardiovascular parameter, including QTcF, at any dose level.
4.2.1.3.3 Respiratory and central nervous systems
Respiratory function (respiratory rate, tidal volume and derived minute volume) and CNS function (a modified Irwin/functional observational battery and detailed clinical observations, including activity, posture, gait, reflexes and body temperature) were evaluated at matched time points. No TILA-278-related effects on respiratory or CNS endpoints were observed at any dose level.
Table 4.2.1-5. Integrated safety pharmacology endpoints (cynomolgus, SC). ^a
| System | Method | Endpoints | Finding |
|---|---|---|---|
| Cardiovascular | Jacketed external telemetry | HR, arterial BP (sys/dia/mean), ECG intervals (RR/PR/QRS/QT/QTcF), waveform | No test-article-related effect at ≤100 mg/kg |
| Respiratory | Respiratory monitoring | Rate, tidal volume, minute volume | No test-article-related effect at ≤100 mg/kg |
| CNS | Modified Irwin / FOB + clinical observation | Activity, posture, gait, reflexes, body temperature | No test-article-related effect at ≤100 mg/kg |
^a No-observed-adverse-effect-level (NOAEL) for safety pharmacology = 100 mg/kg (highest dose). Exposure-margin values are.
4.2.1.3.4 QT/hERG assessment and waiver rationale
A dedicated in vitro hERG (I_Kr) assay and a stand-alone thorough QT study were not conducted. As a large humanised protein, TILA-278 does not access intracellular ion-channel binding sites, has no structural features associated with direct channel block, and is not expected to affect cardiac repolarisation. In accordance with ICH S7B and ICH E14 principles as applied to biotechnology-derived proteins (ICH S6(R1)), in vivo cardiovascular telemetry in the pharmacologically relevant species (Section 4.2.1.3.2), which included quantitative QT/QTcF assessment with no effects, is considered an adequate basis to conclude a low risk of QT prolongation and to support the FIH programme without a dedicated clinical thorough QT study.
4.2.1.3.5 Safety pharmacology conclusion
TILA-278 produced no adverse effects on cardiovascular, respiratory or CNS function at doses up to 100 mg/kg SC, the highest dose tested, establishing a safety-pharmacology NOAEL of 100 mg/kg and a substantial exposure margin over the anticipated clinical exposure at the High dose. These findings support the vital-organ-system safety of TILA-278 for FIH administration.
4.2.1.4 Pharmacodynamic Drug Interactions
No dedicated nonclinical pharmacodynamic drug-interaction studies were conducted. TILA-278 acts through highly selective engagement of two specific human targets (Section 4.2.1.2.1) and is a protein therapeutic that is catabolised to peptides and amino acids; it is neither a substrate nor a modulator of cytochrome P450 enzymes or drug transporters, and no pharmacokinetic drug-interaction liability of that type is anticipated for a monoclonal antibody. The intended intramolecular pharmacodynamic interaction — coupling of TL1A neutralisation with IL-22R agonism — is the therapeutic hypothesis itself and is characterised within Primary Pharmacodynamics (Section 4.2.1.1). Potential additive immunomodulation arising from concomitant immunosuppressants is addressed in the clinical pharmacology and clinical safety documentation (Modules 2.7 and 5).
4.2.1.5 Integrated conclusion
The nonclinical pharmacology package establishes that TILA-278 is a potent, selective bispecific antibody that simultaneously neutralises TL1A and agonises the IL-22 receptor. In vitro, both activities were confirmed with high-affinity, species-specific binding to human and cynomolgus targets and full functional potency, including activity in human colonic epithelial organoids and inflamed human mucosa. Because the targets are not engaged in conventional rodents, in vivo proof of the dual mechanism was demonstrated with the species-matched surrogate mVB-278, which reduced inflammation, promoted mucosal healing and mitigated fibrosis across complementary models of colitis in a dose- and exposure-ordered manner. Secondary pharmacology confirmed target selectivity with no meaningful off-target binding, cytokine release or effector-function liability. Safety pharmacology, assessed under GLP within the pivotal cynomolgus repeat-dose study, revealed no adverse cardiovascular (including QT/QTcF), respiratory or CNS effects up to 100 mg/kg SC. Collectively, these data substantiate the mechanism of action and support the first-in-human safety of TILA-278 for the treatment of moderate-to-severe ulcerative colitis.
Comments (0)
No comments yet. Be the first to say something!